INTRODUCTION

Reactive arthritis (ReA) is a seronegative spondyloarthropathy following urogenital and gastrointestinal tract infection over several weeks, typically characterized by large joint oligoarthritis and negative synovial fluid cultures. ReA has been described following gonococcal and chlamydial urethritis as well as enteritis caused by certain Campylobacter, Shigella, and Salmonella species, in association with HLA-B27 positivity in 50%–80% of patients.

Cases of ReA associated with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being described in the literature. These cases are characterized by asymmetric oligoarthritis one to six weeks following symptomatic respiratory infection with SARS-CoV-2. We describe here a case of ReA with silent thyroiditis following SARS-CoV-2 infection.
weakness greater on the left than right, bilateral absent ankle jerks, and bilateral moderately decreased vibration sense in his toes. Upper extremity strength and sensation were normal. Creatine kinase (CK) was 73 U/L, C-reactive protein (CRP) was 3.5 mg/L, erythrocyte sedimentation rate (ESR) was 21 mm/h, and B12 was 468 pg/mL. Noncontrast magnetic resonance imaging (MRI) of thoracic and lumbar spine showed multilevel degenerative disc disease without severe canal stenosis or cord compression. Lumbar puncture (LP) revealed normal opening pressure, no nucleated cells, protein 54 mg/dl, glucose 60 mg/dl, and negative cerebrospinal fluid (CSF) gram stain and culture. Electrodiagnostic studies (EMG/NCS) were normal. MRI thoracic and lumbar spine showed multilevel degenerative disc disease without severe canal stenosis or cord compression. MRI and complement panels were unremarkable.

Recovery of the patient's pain was slow, and he was not able to return to work. At the time of the last follow-up, he had recovered to 4/5 strength in his bilateral lower extremities but continued to have some weakness in the left hip. Muscle bulk and tone were normal, and bilateral lower extremity strength was 4/5 with limitation due to pain. Sensation was intact to light touch. He developed fever up to 39.5°C and tested positive for SARS-CoV-2 on PCR testing. White blood cell count was initially 4,700 cells/µl with lymphopenia to 500 cells/µl, but this later recovered. Creatinine, liver function tests, viral, and paraneoplastic panels were unremarkable.

Noncontrast magnetic resonance imaging (MRI) of the pelvis with and without contrast revealed edema and enhancement along the bilateral semimembranosus and rectus femoris origins and hip joint capsule (Figure 1). EMG/NCS of the right upper and lower extremities revealed no evidence of acute inflammatory demyelinating polyneuropathy, myopathy, or radiculopathy. EMG was repeated showing clear fluid, 1 WBC, 0 RBCs, glucose 66 mg/dl, and protein 38 mg/dl. Serum and CSF Lyme, autoimmune, viral, and paraneoplastic panels were unremarkable. Rheumatologic workup was negative for HLA-B27 and antibody testing was negative (ANA, dsDNA, Smith, RNP, Chromatin, SS-A/SS-B, ANCA, and acetylcholine receptor). Serum RPR and urine chlamydia and gonorrhea testing were negative. Ultimately, rheumatologist diagnosed the patient with reactive arthritis secondary to his SARS-CoV-2 infection. It was thought that the patient had initially been infected in January after his work exposures and his SARS-CoV-2 PCR test remained positive because he was within 90 days of his initial infection. He was discharged on nonsteroidal anti-inflammatory drugs (NSAIDs) and prednisone 15 mg twice daily with significant relief in pain but not complete return to baseline functioning.

Over the next few months, the patient's bilateral hip and shoulder pain returned as his steroids were tapered. Follow-up MRI pelvis one month after his initial MRI showed the resolution of the enthesitis (Figure 2). A diagnosis of polymyalgia rheumatica or giant cell arteritis was considered but the patient declined a temporal artery biopsy. He was trialed on sulfasalazine without success and ultimately was maintained on prednisone and minocycline, with partial resolution of his symptoms.

During hospitalization for increased pain in April 2021, he was also noted to have some heat intolerance, palpitations, and increased anxiety. TSH was 0.015 and free T4 was elevated to 1.92 and at endocrinology follow-up in May 2021, TSH was suppressed to <0.005 and free T4 was up to 1.95. He had no anterior neck pain or swelling. Chest CT angiography done in February 2021 as part of his lung cancer follow-up did not note any thyroid nodules. Since thyroid peroxidase (TPO), thyroglobulin (Tg) antibodies, and thyroid-stimulating immunoglobulin (TSI) were negative, autoimmune thyroid disease was less likely. Radioactive iodine uptake scan showed diffusely decreased uptake at 4 and 24 h (Figure 3), consistent with silent thyroiditis triggered by SARS-CoV-2 infection. He received supportive treatment with propranolol and by November 2021; the patient was euthyroid.

![Figure 1](image-url)  
**Figure 1** Initial MRI pelvis with and without contrast with nonspecific edema and enhancement along the bilateral semimembranosus and rectus femoris origins.
DISCUSSION

We present a case of reactive arthritis and silent thyroiditis that developed after SARS-CoV-2 infection. The patient had elevated inflammatory markers and MRI evidence of synovitis and enthesitis that resolved after glucocorticoids. He developed a transient period of hyperthyroidism that ultimately resolved with supportive care. Symptoms recurred with tapering the prednisone, and sulfasalazine was initiated before transitioning to minocycline and maintenance steroids.

The patient developed muscle pain and weakness initially in early January 2021, about three weeks before his first SARS-CoV-2 PCR test was performed. He had multiple coworkers who were diagnosed with COVID-19 in January and was likely initially infected at this time, but the patient did not seek out testing because of his atypical presentation. His positive SARS-CoV-2 PCR test a few weeks into his illness likely reflected an earlier infection, as it is known that PCR tests can remain positive for up to 90 days after the initial infection and not necessarily reflect acute infection. The patient did not have the respiratory symptoms of typical...
COVID-19, but we attributed his reactive arthritis and silent thyroiditis to SARS-CoV-2 after extensive serologic and imaging workup for other etiologies was unrevealing. To date, there have been at least 16 cases reported of ReA associated with SARS-CoV-2 infection. A PubMed database search was conducted on April 21, 2021, with the search term “COVID-19 reactive arthritis”, and case reports and reviews of oligoarthritis in adult patients following SARS-CoV-2 infection were selected for further review. Additional reports that are not in the database search but referenced in the selected publications were also included. The articles are summarized in Table 1.

### Table 1: Reported cases and series of reactive arthritis following SARS-CoV-2 infection in PubMed database

| Author                  | Year | Timeline of arthritis after SARS-CoV-2 positivity | Treatment                                      | Outcome              |
|-------------------------|------|--------------------------------------------------|------------------------------------------------|----------------------|
| Ono et al.⁶             | 2020 | Ankle arthritis and Achilles tendon enthesitis 3 weeks after positive test | NSAIDs and intra-articular steroids             | Clinical improvement |
| Saricaoglu et al.⁷      | 2020 | Arthritis of MTP and interphalangeal joints of the feet 1 week after positive test | NSAIDs                                          | Resolution           |
| Jali⁸                   | 2020 | Arthritis of interphalangeal joints of the hands 3 weeks after positive test | Celecoxib                                       | Resolution           |
| Liew et al.⁹            | 2020 | Arthritis of right knee at time of positive test, exposure thought to be one week prior | Etoricoxib and intra-articular steroids         | Clinical improvement |
| Fragata and Mourao⁴     | 2020 | Arthritis of MCP and interphalangeal joints of the hands 4 weeks after first positive test | Steroids                                        | Resolution           |
| Honge et al.⁵           | 2021 | Fever and knee, ankle arthritis 2 weeks after positive test | Ibuprofen and prednisolone                     | Resolution           |
| Coath et al.¹⁰          | 2021 | Sacroiliac arthritis at time of positive test, with preceding exposure and suggestive symptoms of SARS-CoV−2 | Intramuscular methylprednisolone and diclofenac | Resolution           |
| Schenker et al.¹¹       | 2021 | Arthritis of ankles, wrists, and knees 2–3 weeks following positive test | Prednisolone                                    | Resolution           |
| De Stefano et al.¹²     | 2020 | Elbow arthritis and psoriasis-form rash 1–2 weeks following positive test | NSAIDs and topical steroids for rash            | Resolution           |
| Danssaert et al.¹³      | 2020 | Hand arthritis 1–2 weeks following positive test | Topical diclofenac, hydromorphone, gabapentin, and later tramadol and occupational therapy | Clinical improvement |
| Gasparotto et al.¹⁴     | 2021 | Ankle, knee, and hip arthritis 4–5 weeks after positive test | Ibuprofen                                       | Resolution           |
| Parisi et al.¹⁵          | 2020 | Ankle arthritis 3–4 weeks following positive test | Ibuprofen                                       | Clinical improvement |
| Yokogawa et al.¹⁶       | 2020 | Fever and wrist, shoulder, and knee arthritis 2 weeks after positive test | None                                             | Spontaneous resolution |
| Lopez-Gonzalez et al.¹⁷ | 2020 | Four cases occurring after symptom onset 1. First MTP (8 days) 2. Ankle (19 days) 3. Knees (8 days) 4. Knee and ankle (27 days) | 1. Colchicine and intra-articular steroids 2. Colchicine and oral prednisone 3. Intra-articular steroids 4. Colchicine | Resolution in all cases |
| Di Carlo et al.¹⁸       | 2021 | Ankle arthritis 5 weeks after positive test | Methylprednisolone                              | Clinical improvement (continued on steroids as of publication) |
| Sureja and Nandamuri¹⁹  | 2021 | Hand, knee, ankle, and foot arthritis 2 weeks after positive test | NSAIDs, tapering steroids, opiates              | Resolution           |
Clinical manifestations of ReA are variable and include several articular as well as extra-articular manifestations, including asymmetric mono- or oligo-arthritis (involving 2–4 joints) days to weeks after enteric or genital urinary pathogens, without crystalline arthritis.3,20,21 ReA is typically an oligoarthritis of lower extremity joints (as in our case) but may present with polyarthritis of hand joints with dactylitis.20 The axial skeleton may be involved with sacroiliac joint synovitis and enthesitis, and extra-articular involvement includes uveitis/conjunctivitis, urethritis/cervicitis, rash, aphthous ulcers, and more rarely aortitis and cardiac conduction abnormalities.20

Both silent and subacute thyroiditis after SARS-CoV-2 infection have been reported. Subacute thyroiditis often presents with fever and anterior neck pain whereas silent thyroiditis is painless, but both are self-limited.22–24 Our patient was febrile initially but had no neck pain and normal thyroid function initially. He went on to develop complete TSH suppression with an elevated free T4 without any associated neck pain, most consistent with a silent thyroiditis. Steroid use could have contributed to low TSH but not elevated free T4. The Jod–Basedow effect from iodinated contrast could not explain persistent hyperthyroidism three months after exposure.

Diagnosis of thyroiditis is made clinically with laboratory investigations, and in some cases, a radioactive iodine uptakes scan to rule out Graves’ disease.24 Histopathology in SARS-CoV-2 thyroiditis shows interstitial infiltration by lymphocytes and destruction of follicular cells.24,25 The treatment of subacute and silent thyroiditis is supportive as the thyroid dysfunction in most cases is transient. NSAIDs can be used in mild cases of neck pain and glucocorticoids for severe cases, while beta blockers and levothyroxine can be used for tachyarrhythmias and hypothyroidism.24

Treatment of ReA is aimed at reducing articular and extra-articular inflammation and increasing mobility: NSAIDs are the first-line therapy, with systemic corticosteroids reserved for refractory or severe disease of long duration.26 Methotrexate, sulfasalazine, and azathioprine also have demonstrated efficacy in treating disease refractory to corticosteroids.26 Our patient had significant relief on an initial course of NSAIDs required several prednisone tapers due to the severity and duration of his disease (overall course greater than 3 months). He was initiated on sulfasalazine without success and was later started on minocycline. As of his most recent follow-up, he had not completely returned to baseline.

4 | CONCLUSION

ReA typically manifests as oligoarthritis of the lower extremities several weeks following enteric or genital urinary infection, and in some cases, viral and streptococcal infections. Our patient had asymmetric oligoarthritis and imaging showing enthesitis with elevated acute phase reactants after SARS-CoV-2 infection, along with suppressed TSH and elevated free T4, all of which favors the diagnosis of ReA and silent thyroiditis secondary to SARS-CoV-2 infection. He continues to have incomplete clinical resolution of the arthralgias despite resolved enthesitis. Several cases of ReA and thyroiditis due to the pandemic virus SARS-CoV-2 have been published, and it is expected that more cases and series will be reported in the coming months given the widespread global scale of the pandemic.

ACKNOWLEDGEMENT

The authors thank Dr. Gene Kitamura, Department of Radiology, University of Pittsburgh, for providing the MRI images used in this article.

CONFLICT OF INTEREST

There are no conflicts of interest to report.

AUTHOR CONTRIBUTIONS

Jacob Quaytman and Shashank Suresh gathered data and prepared manuscript. Usha Gollamudi and Noah Bass reviewed and edited the manuscript.

ETHICAL APPROVAL

The research complies with the Declaration of Helsinki.

CONSENT

Written consent was obtained from the patient described in this case report prior to publication.

DATA AVAILABILITY STATEMENT

All data are included in this article but additional data available on request due to privacy/ethical restrictions.

ORCID

Jacob Quaytman https://orcid.org/0000-0003-0215-9237

REFERENCES

1. Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13(4-5):546-549. doi:10.1016/j.autrev.2014.01.005. Epub 2014 Jan 10. PMID: 24418301.
2. Pennisi M, Perdue J, Roulston T, Nicholas J, Schmidt E, Rolfs J. An overview of reactive arthritis. JAAQA. 2019;32(7):25-28. doi:10.1097/01.JAA.0000558320.47868.2f. PMID: 31169570.
3. Schmitt SK. Reactive arthritis. Infect Dis Clin North Am. 2017;31(2):265-277. doi:10.1016/j.idc.2017.01.002. Epub 2017 Mar 11 PMID: 28292540.
4. Fragata I, Mourão AF. Coronavirus disease 19 (COVID-19) complicated with post-viral arthritis. Acta Reumatol Port. 2020;45(4):278-280. English. PMID: 33420769.
5. Houge BL, Hermansen MF, Storgaard M. Reactive arthritis after COVID-19. *BMJ Case Rep*. 2021;14(3):e241375. doi:10.1136/bcr-2020-241375. PMID: 33653867; PMCID: PMC7929821.

6. Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. *RMD Open*. 2020;6(2):e001350. doi:10.1136/rmdopen-2020-001350. PMID: 32763956; PMCID: PMC7722270.

7. Saracioğlu EM, Hasanoglu I, Guner R. The first reactive arthritis case associated with COVID-19. *J Med Virol*. 2021;93(1):192-193. doi:10.1002/jmv.26296. Epub 2020 Jul 19. PMID: 32652541; PMCID: PMC7405389.

8. Jali I. Reactive arthritis after COVID-19 infection. *Curr Rheumatol Rep*. 2020;12(11):e11761. doi:10.7759/currheumrep.11761. PMID: 33409010; PMCID: PMC7779130.

9. Liew IY, Mak TM, Cui L, Vasoo S, Lim XR. A case of reactive arthritis secondary to coronavirus disease 2019 infection. *J Clin Rheumatol*. 2020;26(6):233. doi:10.1097/RHU.0000000000001056. PMID: 32694352; PMCID: PMC7437408.

10. Coath FL, Mackay J, Gaffney JK. Axial presentation of reactive arthritis secondary to Covid-19 infection. *Rheumatology (Oxford)*. 2021;60(7):e232-e233. doi:10.1093/rheumatology/keab009. Epub ahead of print. PMID: 33471106; PMCID: PMC7928576.

11. Schenker HM, Hagen M, Simon D, Schett G, Manger B. Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. *Rheumatology (Oxford)*. 2021;60(1):479-480. doi:10.1093/rheumatology/keaa689. PMID: 33200974; PMCID: PMC7717428.

12. De Stefano L, Rossi S, Montecucco C, Bugatti T. Subclinical monoarthritis and psoriatic skin lesions following COVID-19. *Ann Rheum Dis*. 2020;70:218-2026. Epub ahead of print. PMID: 32753423.

13. Danssaert Z, Raem T, Hemtasilpa S. Reactive arthritis in a 37-Year-old female with SARS-CoV2 infection. *Cureus*. 2020;12(8):e9698. doi:10.7759/cureus.9698. PMID: 32923288; PMCID: PMC7486113.

14. Gasparotto M, Framba V, Piovella C, Doria A, Iaccarino L. Post-COVID-19 arthritis: a case report and literature review. *Clin Rheumatol*. 2021;40(8):1-6. doi:10.1007/s10067-020-05550-1. Epub ahead of print. PMID: 33587197; PMCID: PMC7882861.

15. Parisi S, Borrelli R, Bianchi S, Fusaro E. Viral arthritis and COVID-19. *Lancet Rheumatol*. 2020;2(11):e655-e657. doi:10.1016/S2665-9913(20)30489-9. Epub 2020 Oct 5. PMID: 33043303; PMCID: PMC7535796.

16. Yokogawa N, Minematsu N, Katano H, Suzuki T. Case of acute arthritis following SARS-CoV-2 infection. *Ann Rheum Dis*. 2020;79:80-101. doi:10.1136/annrheumdis-2020-218281. Epub ahead of print. PMID: 32591356.

17. López-González MD, Peral-Garrido ML, Calabuig I, et al. Case series of acute arthritis during COVID-19 admission. *Ann Rheum Dis*. 2020;80:e58. doi:10.1136/annrheumdis-2020-217914. Epub ahead of print. PMID: 32471899.

18. Di Carlo M, Tardella M, Salaffi F. Can SARS-CoV-2 induce reactive arthritis? *Clin Exp Rheumatol*. 2021;39(1):25-26. Epub 2021 Jan 15. PMID: 33506755.

19. Sureja NP, Nandamuri D. Reactive arthritis after SARS-CoV-2 infection. *Rheumatol Adv Pract*. 2021;5(1):rka001. doi:10.1093/rhap/rka001. PMID: 33615130; PMCID: PMC7882147.

20. García-Kutzbach A, Chacón-Súchite J, García-Ferrer H, Iraheta I. Reactive arthritis: update 2018. *Clin Rheumatol*. 2018;37(4):869-874. doi:10.1007/s10067-018-4022-5. Epub 2018 Feb 17 PMID: 29455267.

21. Wakefield RJ, Green MJ, Marzo-Ortega H, et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. *Ann Rheum Dis*. 2004;63(4):382-385. doi:10.1136/ard.2003.007062. PMID: 15020331; PMCID: PMC1754934.

22. Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis. *Lancet Diabetes Endocrinol*. 2020;8(9):739-741. doi:10.1016/S2213-8587(20)30266-7. Epub 2020 Jul 30. PMID: 32738929; PMCID: PMC7392564.

23. Asfueroğlu Kalkan E, Ates I. A case of subacute thyroiditis associated with Covid-19 infection. *J Endocrinol Invest*. 2020;43(8):1173-1174. doi:10.1016/s0406-1820-01316-3. Epub 2020 Jun 5. PMID: 32504458; PMCID: PMC7273820.

24. Mattar SAM, Koh S1Q, Rama Chandran S, Cherng BPZ. Subacute thyroiditis associated with COVID-19. *BMJ Case Rep*. 2020;13(8):e237336. doi:10.1136/bcr-2020-237336. PMID: 32843467; PMCID: PMC7449350.

25. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimbo P. Impact of COVID-19 on the thyroid gland: an update. *Rev Endor Metab Disord*. 2020;22(4):803-815. doi:10.1007/s11154-020-09615-z. Epub ahead of print. PMID: 33241508; PMCID: PMC7688298.

26. Kwiatkowska B, Filipowicz-Sosnowska A. Reactive arthritis. *Pol Arch Med Wewn*. 2009;119(1-2):60-65. PMID: 19341180.

---

**How to cite this article:** Quaytman J, Gollamudi U, Bass N, Suresh S. Reactive arthritis and silent thyroiditis following SARS-CoV-2 infection: Case report and review of the literature. *Clin Case Rep*. 2022;10:e05430. doi:10.1002/ccr3.5430